GBT Announces Positive 24-week Results from Phase 3 HOPE Study

GBT: Global Blood Therapeutics, Inc.
2018-12-03 10:00:00
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile